Viola Zhu, MD, PhD of UC Irvine Health discusses the ALEX trial and the use of alectinib and crizotinib in ALK+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract LBA9008: ALEX: Alectinib versus Crizotinib in ALK+ NSCLC at the First-Line Setting.
Advertisement